多西紫杉醇联合表阿霉素及环磷酰胺治疗晚期乳腺癌的临床观察

Docetaxel combined with epirubicin and cyclophosphamide in treatment of advanced breast cancer

目的:观察多西紫杉醇联合表阿霉素及环磷酰胺治疗晚期乳腺癌的疗效与不良反应。方法:采用多西紫杉醇联合表阿霉素及环磷酰胺治疗56例复发或转移的晚期乳腺癌患者,多西紫杉醇75mg/m2,d1,表阿霉素50mg/m2,d1,环磷酰胺500mg/m2,d1,21天为1周期,连续治疗2周期。结果:56例患者TEC方案治疗2周期后CR7例,PR22例,总有效率为51.8%。最常见不良反应为骨髓抑制、消化道反应及脱发,本组无一例发生过敏反应,其不良反应可耐受。结论:TEC方案治疗晚期乳腺癌可作为晚期乳腺癌的一线治疗方案。

Objective： To observe the effect of docetaxel and epirubicin and cyclophosphamide in treatment of advanced breast cancer. Methods： Combined docetaxel and epirubicin and cyclophosphamide was used for 56 cases of recurrence or metastasis patients with advanced breast cancer, docetaxel 75mg/m2, d1, epirubicin 50mg/m2, d1, cyclophosphamide 500mg/m2, d1, 21 days as a cycle, two consecutive treatment cycles. Results： For 56 patients, overall responserate was 51.8%. The most common adverse events were bone marrow suppression, gastrointestinal reactions and hair loss, no allergic reaction occurs, toxicity can be tolerated. Conclusion： TEC can be used as first-line treatment of advanced breast cancer.